Cerebrospinal Fluid Alzheimer’s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort
Inger van Steenoven(Amsterdam UMC Location VUmc), Afina W. Lemstra(Amsterdam Neuroscience), Daniel Weintraub(California University of Pennsylvania), Dag Aarsland(King's College London), Laura Bonanni(School of the Art Institute of Chicago), Tormod Fladby(University of Oslo), Charlotte E. Teunissen(Amsterdam Neuroscience), Brit Mollenhauer(Paracelsus Elena Klinik Kassel), Elisabet Londos(Lund University), Milica G. Kramberger(Ljubljana University Medical Centre), Frederic Blanc(Centre National de la Recherche Scientifique), Wiesje M. van der Flier(Amsterdam Neuroscience)
Cited by 122
Related Papers
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk
|Nature Genetics|2019|2.5k
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k